Consolidation immunotherapy with durvalumab in the treatment of locally advanced non‑small cell lung cancer

01/2021

MUDr. Ondřej Bílek

Klinika komplexní onkologické péče LF MU a Masarykův onkologický ústav, Brno

SUMMARY

In about a quarter of cases, non-small cell lung cancer (NSCLC) is diagnosed at the stage of locally advanced disease. The standard treatment for these patients is concomitant chemotherapy and radiotherapy. Currently, immunotherapy is an integral part of the treatment of the NSCLC treatment algorithm, especially anti-PD-1 and anti-PD-L1 check-point inhibitors. Data from the PACIFIC study demonstrated a significant benefit of consolidating immunotherapy with the anti-PD-L1 monoclonal antibody durvalumab after cessation of radiotherapy, including prolongation of overall survival. Durvalumab is currently the reference molecule in this indication. Tolerance and safety profile are favorable, early diagnosis and treatment of immune-related adverse events is necessary.

Key words

non-small cell lung cancer, immunotherapy, durvalumab